|
|
| |
|
|
| 本文已被：浏览 5次 下载 3次 |
码上扫一扫！ |
| 强力定眩片联合盐酸氟桂利嗪对脑动脉硬化性眩晕疗效及安全性的Meta分析 |
| 吴善北,陈 炜,杨富才,卓桂锋,吴 林 |
|
|
| (1.广西中医药大学，广西 南宁，530022;2.广西中医药大学第一附属医院，广西 南宁，530023;3.广西中医药大学科学实验中心，广西 南宁，530022) |
|
| 摘要: |
| 目的：对强力定眩片联合盐酸氟桂利嗪治疗脑动脉硬化性眩晕的临床疗效及安全性进行Meta分析。方法：检索中国知网（China National Knowledge Infrastructure，CNKI）、维普中文科技期刊数据库（VIP）、万方数据（WANFANG DATA） 、中国生物医学文献服务系统（Chinese Biomedical Literature Service System，SinoMed）、中华医学期刊全文数据库（Chinese Medical Association Journal Database）、PubMed、Web of Science、Embase、Cochrane Library、Karger从建库至2025年9月10日有关强力定眩片联合盐酸氟桂利嗪治疗脑动脉硬化性眩晕的随机对照研究（randomized controlled trial，RCT），提取资料并使用Cochrane Reviewers Handbook中的偏倚风险评估工具对纳入研究的偏倚风险进行评价，并运用Review Manager 5.3软件对相关数据进行统计学分析。结果：最终纳入13篇文献，总样本量1 138例，其中对照组557例，试验组581例。Meta分析结果显示：中西医结合试验组总有效率［RR=1.23，95%CI（1.16，1.30），P<0.000 01］、眩晕评分［MD=-0.59，95%CI（-0.65，-0.52），P<0.000 01］、平衡障碍评分［MD=-0.49，95%CI（-0.70，-0.27），P<0.000 1］、听力障碍评分［MD=-0.53，95%CI（-0.63，-0.42），P<0.000 01］、耳鸣评分［MD=-0.48，95%CI（-0.63，-0.33），P<0.000 01］、自主神经功能紊乱评分［MD=-0.71，95%CI（-0.80，-0.61），P<0.000 01］、头痛评分［MD=-0.54，95%CI（-0.63，-0.45），P<0.000 01］、血液黏度［MD=-0.48，95%CI（-0.58，-0.38），P<0.000 01］、全血高切黏度［MD=-1.27，95%CI（-1.60，-0.93），P<0.000 01］、全血低切黏度［MD=-2.51，95%CI（-3.24，-1.79），P<0.000 01］、纤维蛋白原［MD=-1.03，95%CI（-1.37，-0.70），P<0.000 01］、左椎动脉平均流速［MD=4.52，95%CI（3.88，5.15），P<0.000 01］、右椎动脉平均流速［MD=4.61，95%CI（3.98，5.24），P<0.000 01］、基底动脉平均流速［MD=4.81，95%CI（3.87，5.75），P<0.000 01］、大脑中动脉平均流速［MD=6.81，95%CI（2.61，11.01），P=0.001］均优于对照组，差异具有统计学意义；二者不良反应发生率的差异无统计学意义［RR=1.09，95%CI（0.75，1.59），P=0.65］。结论：相较西医治疗，中西医结合治疗在多方面具有增效作用，且不会增加不良反应发生率。 |
| 关键词: 脑动脉硬化性 眩晕 强力定眩片 盐酸氟桂利嗪 随机对照试验 Meta分析 |
| DOI： |
|
|
| Efficacy and safety of Qiangli Dingxuan tablets combined with flunarizine hydrochloride in treatment of cerebral arteriosclerotic vertigo: A meta-analysis |
| WU Shanbei,CHEN Wei,YANG Fucai,ZHUO Guifeng,WU Lin |
| (1. Guangxi University of Chinese Medicine, Nanning 530022, Guangxi, China;;2. The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi, China;1. Guangxi University of Chinese Medicine, Nanning 530022, Guangxi, China; 3. Scientific Experimental Center, Guangxi University of Chinese Medicine, Nanning 530022, Guangxi, China) |
| Abstract: |
| Objective: To investigate the efficacy and safety of Qiangli Dingxuan tablets combined with flunarizine hydrochloride in the treatment of cerebral arteriosclerotic vertigo through a meta-analysis. Methods: CNKI, VIP, Wanfang Data, SinoMed, Chinese Medical Association Journal Database, PubMed, Web of Science, Embase, the Cochrane Library, and Karger were searched for randomized controlled trials on Qiangli Dingxuan tablets combined with flunarizine hydrochloride in the treatment of cerebral arteriosclerotic vertigo published up to September 10, 2025. Related data were extracted, the tool for assessing risk of bias in Cochrane Reviewers Handbook was used to assess the risk of bias of the studies included in this analysis. Review Manager 5.3 was used to perform a statistical analysis of related data. Results: A total of 13 articles were included, involving 1138 patients in total, and there were 557 patients in the control group and 581 patients in the experimental group. The meta-analysis showed that compared with the control group, the integrated traditional Chinese and Western medicine experimental group had significantly better results in terms of overall response rate （risk ratio ［RR］ = 1.23，95% confidence interval ［CI］: 1.16-1.30,P< 0.000 01）, vertigo score （mean difference ［MD］ = -0.59, 95% CI: -0.65 to -0.52,P<0.000 01）, balance disorder score （MD = -0.49, 95% CI: -0.70 to -0.27,P<0.000 1）, hearing disorder score （MD = -0.53, 95% CI: -0.63 to -0.42,P<0.000 01）, tinnitus score （MD = -0.48, 95% CI: -0.63 to -0.33,P<0.000 01）, autonomic dysfunction score （MD = -0.71, 95% CI: -0.80 to -0.61,P<0.000 01）, headache score （MD = -0.54, 95% CI: -0.63 to -0.45,P<0.000 01）, blood viscosity （MD = -0.48, 95% CI: -0.58 to -0.38,P< 0.000 01）, high-shear blood viscosity （MD = -1.27, 95% CI: -1.60 to -0.93,P<0.000 01）, low-shear blood viscosity （MD = -2.51, 95% CI: -3.24 to -1.79,P< 0.000 01）, fibrinogen （MD = -1.03, 95% CI: -1.37 to -0.70, P<0.000 01）, mean flow velocity of the left vertebral artery （MD = 4.52, 95% CI: 3.88-5.15,P<0.000 01）, mean flow velocity of the right vertebral artery （MD = 4.61, 95% CI: 3.98-5.24,P<0.000 01）, mean flow velocity of the basilar artery （MD = 4.81, 95% CI: 3.87-5.75,P<0.000 01）, and mean flow velocity of the middle cerebral artery （MD = 6.81, 95% CI: 2.61-11.01,P=0.001）. There was no significant difference in the incidence rate of adverse reactions between the two groups （RR = 1.09, 95% CI: 0.75-1.59,P=0.65）. Compared with Western medicine treatment, integrated traditional Chinese and Western medicine therapy can improve the treatment outcome from multiple aspects, without increasing the incidence rate of adverse reactions. |
| Key words: cerebral arteriosclerotic vertigo Qiangli Dingxuan tablets flunarizine hydrochloride randomized controlled trial meta-analysis |
|
|
|
|
|
